Alexander Minidis, PhD
Chief Science Officer
Alexander is a co-founder of EvoMediCon AB and is responsible for the due diligence and development of medicinal chemistry projects. Alexander brings his vast experience in drug design and project leadership to the company. During his career he has been involved in most major aspects of the drug discovery process, from molecular modeling and ADME, to safety aspects as well as many other features. Alexander’s essential role in EvoMediCon is to enable success for the most challenging medicinal chemistry projects.
Alexander obtained his PhD in organic chemistry in 1997 at the University of Basel, Switzerland, under the supervision of Prof. A. Pfaltz. He then spent 6 months as post-doctorate at the Max-Planck-Institut f. Kohlenforschung in Mülheim, Germany, under Prof. Donna Blackmond followed by a one year post-doctorate at the University of Stockholm, Sweden, under Prof. J.E. Bäckvall. During his professional career, Alexander has had held various positions within the realm of drug discovery to include team and project leadership, as well as coordinating external collaborations
Peter Söderman, PhD
As a co-founder of EvoMediCon AB, Peter's role is business development and business intelligence. He actively conributes to the development of EvoMediCon's project platform and to strengthening EvoMediCon's portfolio.
His extensive experience in project managment and lean activities brings esteemed value to the company and subsequently to our customers.
Peter studied chemistry at Stockholm University where he obtained his PhD in Organic Chemistry under the supervision of Prof. Göran Widmalm. He spent two years as a post-doctorate at MIT with Prof. Barbara Imperiali before he joined AstraZeneca (AZ) in 2000. During his time at AZ Peter became a team and project leader and was involved in business development as well as lean activities.
Fernando F Huerta, PhD
Head of Chemistry
Fernando is a co-founder of EvoMediCon and his area of expertise is in organic synthesis and synthesis design. His role at EvoMediCon is to strengthen synthetic organic chemistry within the drug design process. Evaluation of synthetic accessibility and new synthesis designs is one of many important factors in the production of timely and successful medicinal chemistry projects.
Fernando has a strong background in different areas of organic chemistry in addition to serving as chemistry project leader in medicinal chemistry. During his professional career, he has acted as Associate Professor at the University of Alicante, Spain (2000-2002) before he joined AstraZeneca, Södertälje (2002-2012). During this period he was an integral member of a synthesis specialist team placed in charge of solving various projects’ chemistry problems throughout the organization. In addition, Fernando is also co-founder of Chemnotia AB and MedalChemy SL which are all chemistry related companies.